drugset
drugset / Trial / NCT03123393

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT03123393 ↗

Phase 2 Terminated 49 enrolled Calithera Biosciences, Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy of TAK-659 measured by independent radiologic review committee (IRC)-assessed overall response rate (ORR) in participants with relapsed or refractory DLBCL.

Timeline

Start
2017-10-10
Primary completion
2019-12-17
Completion
2019-12-17

Drugs

EvaluationDrugModalityDoseRoute
Subject mivavotinib Small molecule 60 mg Oral
Subject mivavotinib Small molecule 100 mg Oral

Indications

diffuse large B-cell lymphoma